secwatch.observer — SEC 8-K summary
======================================

Issuer:     AN2 Therapeutics, Inc. (ANTX)
CIK:        0001880438
Form:       8-K
Filed at:   2022-08-11T23:59:59+00:00
Accession:  0000950170-22-016887
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AN2 Therapeutics reports Q2 2022 cash of $115.8M, updates on epetraborole trials
--------------------------------------------------------------------------------

- Cash, cash equivalents and investments $115.8M at June 30, 2022; sufficient to fund operations through mid-2024.
- Enrolling U.S. patients in Phase 2/3 trial of epetraborole for treatment-refractory MAC lung disease; topline Phase 2 results expected mid-2023.
- Completed Phase 1 PK/safety study in Japan; gained PMDA alignment on microbiological primary endpoint for potential registration.
- Maggie FitzPatrick appointed to Board of Directors; she previously led public affairs at Johnson & Johnson.
- R&D and G&A expenses increased due to higher trial activity and expanded post-IPO operations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1880438/000095017022016887/0000950170-22-016887-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1880438/000095017022016887/antx-20220811.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-016887

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer